Publications

Detailed Information

인체 경피 노출을 통한 벤조페논-3의 약물동태학 연구 : Pharmacokinetic features of benzophenone-3 after dermal application in humans

DC Field Value Language
dc.contributor.advisor김성균-
dc.contributor.author이수진-
dc.date.accessioned2018-05-29T04:14:46Z-
dc.date.available2018-05-29T04:14:46Z-
dc.date.issued2018-02-
dc.identifier.other000000149406-
dc.identifier.urihttps://hdl.handle.net/10371/141945-
dc.description학위논문 (석사)-- 서울대학교 대학원 : 보건대학원 환경보건학과, 2018. 2. 김성균.-
dc.description.abstractBenzophenone-3 (BP-3) is a component that blocks ultraviolet rays. It is mainly used in sunscreen agents and functional cosmetics, and is mostly exposed through the skin. several studies have reported the possibility of endocrine disturbance. Whereas pharmacokinetic studies on BP-3 have been reported in animal, it is not well known to the fate of BP-3 in human body following dermal exposure. The aim of this study is to determine pharmacokinetic characteristics of BP-3 in male subjects following single dermal application of 1 mg/cm2 of deuterium labeled BP-3.
Blood and urine were collected for 72 hours and analyzed BP-3 and its metabolites using UPLC-MS/MS. In blood, after peak time eliminated decline two distinct phases in time-profile, while the metabolites followed first-order kinetics. Based on time-profiles, a multi-compartmental model constructed and validated. As a results, unconjugated BP-3 concentration in serum was lower than conjugated BP-3 concentration in serum. But it was similar to that of total BP-1 concentration in serum. Almost of the BP-3 and BP-1 in urine undergo conjugation or demethylation. And the fraction of urinary excretion for conjugated BP-3 (0.76 ± 0.19%) was 4-fold upper than total BP-1 (0.19 ± 0.13%), which was approximately 580-fold upper than unconjugated BP-3 (0.0013 ± 0.0005%). This study provides information on absorption, distribution, metabolism and elimination of BP-3 in human body and the pharmacokinetic model can be utilized for estimating exposure dose of BP-3, contributing to more realistic exposure assessment in the Korean population based upon biomonitoring data.
-
dc.description.tableofcontentsⅠ. Introduction 1

Ⅱ. Materials and methods 5
1. Chemicals and Reagents 5
2. Study Design and Sample Collection 6
3. Analytical procedure 7
3.1. Sample preparation 7
3.1.1 Blood sample preparation 7
3.1.2 Urine sample preparation 8
3.2. UPLC-MS/MS analysis 9
4. Pharmacokinetic analysis 12
4.1. Non-compartmental analysis 12
4.2. Development of the pharmacokinetic model 13

Ⅲ. Results 15
1. Participant characteristics 15
2. Pharmacokinetic characteristics of benzophenone-3 and its metabolites 16
3. Pharmacokinetic modeling 20

Ⅳ. Discussion 27

Ⅴ. Conclusions 32

Ⅵ. References 33

Ⅶ. Supplementary information 38
-
dc.formatapplication/pdf-
dc.format.extent847262 bytes-
dc.format.mediumapplication/pdf-
dc.language.isoko-
dc.publisher서울대학교 대학원-
dc.subjectbezophenone-3-
dc.subjectdermal application-
dc.subjectpharmacokinetic model-
dc.subjectthe fraction of urinary excretion-
dc.subjectabsorption · distribution · metabolism · excretion (ADME)-
dc.subject.ddc363.7-
dc.title인체 경피 노출을 통한 벤조페논-3의 약물동태학 연구-
dc.title.alternativePharmacokinetic features of benzophenone-3 after dermal application in humans-
dc.typeThesis-
dc.contributor.AlternativeAuthorLee, Su Jin-
dc.description.degreeMaster-
dc.contributor.affiliation보건대학원 환경보건학과-
dc.date.awarded2018-02-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share